Sarepta Therapeutics (NASDAQ: SRPT) net income
Sarepta Therapeutics reported a net loss of $713.4m for fiscal 2025; in fiscal 2024 it reported a net profit of $235.2m. Earnings per share were −$7.13.
Sarepta Therapeutics's best year of the last 10 was fiscal 2024. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$713.4m | −403.3% | −32.5% | −$7.13 |
| 2024 | $235.2m | — | 12.4% | $2.47 |
| 2023 | −$536.0m | — | −43.1% | −$5.80 |
| 2022 | −$703.5m | — | −75.4% | −$8.03 |
| 2021 | −$418.8m | — | −59.7% | −$5.15 |
| 2020 | −$554.1m | — | −102.6% | −$7.11 |
| 2019 | −$715.1m | — | −187.8% | — |
| 2018 | −$361.9m | — | −120.2% | — |
| 2017 | −$50.7m | — | −32.8% | — |
| 2016 | −$267.3m | — | −4,930.2% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Sarepta Therapeutics net income compared with its sector
By net income for its latest fiscal year, Sarepta Therapeutics ranks 484th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Sarepta Therapeutics, −32.5%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 482nd | Recursion Pharmaceuticals | −$644.8m | −863.4% |
| 483rd | Vor Biopharma | −$696.0m | — |
| 484th | Sarepta Therapeutics | −$713.4m | −32.5% |
| 485th | BridgeBio Pharma | −$732.9m | −146.0% |
| 486th | Biohaven | −$738.8m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Sarepta Therapeutics
- How much did Sarepta Therapeutics earn in fiscal 2025?
- Sarepta Therapeutics reported a net loss of $713.4m for fiscal 2025. In fiscal 2024 it reported a net profit of $235.2m.
- What are the earnings per share of Sarepta Therapeutics?
- They were −$7.13 in fiscal 2025, compared with $2.47 in fiscal 2024.
- What was the most profitable year for Sarepta Therapeutics?
- Of its last 10 fiscal years, fiscal 2024, with $235.2m.
- Where does Sarepta Therapeutics rank in its sector by net income?
- It ranks 484th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Sarepta Therapeutics come from?
- From the annual report (Form 10-K) that Sarepta Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Sarepta Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Sarepta Therapeutics: the Sarepta Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.